Doribax

Doribax is a brand name of doripenem, approved by the FDA in the following formulation(s):

DORIBAX (doripenem - injectable; iv (infusion))

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: October 12, 2007
  
  Strength(s): 500MG/VIAL ^[RLD]


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: October 5, 2010
  
  Strength(s): 250MG/VIAL
  

Has a generic version of Doribax been approved?

No. There is currently no therapeutically equivalent version of Doribax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Doribax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyrrolidylthiocarbapenem derivative
  Patent 5,317,016
  Issued: May 31, 1994
  Inventor(s): Nishitani; Yasuhiro & Irie; Tadashi
  Assignee(s): Shionogi Seiyaku Kabushiki Kaisha
  A pyrrolidylthiocarbapenem derivative represented by Formula I is provided: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2, R.sup.3 and R.sup.4 are hydrogen, lower alkyl which can be substituted or an amino protecting group independently, or R.sup.2 and R.sup.3 together with a nitrogen atom to which R.sup.2 and R.sup.3 are bonded form a saturated or unsaturated cyclic group, or R.sup.2 and R.sup.4, or R.sup.3 and R.sup.4 together with two nitrogen atoms and one sulfur atom in the sufamide group form a saturated or unsaturated cyclic group; each cyclic group can further include at least one atom selected from the group consisting of oxygen, sulfur and nitrogen, and each cyclic group can be substituted; X.sup.1 is hydrogen or a hydroxy protecting group; X.sup.2 is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and Y.sup.2 is hydrogen or an amino protecting group.
  
  Patent expiration dates:
  
  
  • June 5, 2015
    
    ✓ 
    Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 12, 2012 - NEW CHEMICAL ENTITY
  
  

See also...

• Doribax Consumer Information (Drugs.com)
• Doribax Consumer Information (Wolters Kluwer)
• Doribax Consumer Information (Cerner Multum)
• Doribax Advanced Consumer Information (Micromedex)
• Doribax AHFS DI Monographs (ASHP)
• Doripenem Consumer Information (Wolters Kluwer)
• Doripenem Consumer Information (Cerner Multum)
• Doripenem Intravenous Advanced Consumer Information (Micromedex)
• Doripenem AHFS DI Monographs (ASHP)